Subscribe To
replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
replimune: q4 2023 data readouts of rp1 makes this a must watch
replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo...
August 14, 2023, 5:28 pm
replimune: the rise of oncolytic virus therapies in cancer treatment
The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from ...
July 9, 2023, 1:22 am
replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses...
June 3, 2023, 6:15 pm
Is a surprise coming for replimune (repl) this earnings season?
replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earni...
May 17, 2023, 11:16 am
replimune group, inc. (repl) loses -14.58% in 4 weeks, here's why a trend reversal may be around the corner
replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure mi...
February 24, 2023, 11:18 am
replimune group, inc. (repl) is on the move, here's why the trend could be sustainable
replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize o...
February 9, 2023, 10:34 am
Recent price trend in replimune group, inc. (repl) is your friend, here's why
replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great ch...
January 6, 2023, 10:32 am
Revisiting replimune
Today, we revisit an intriguing oncology developmental company called replimune Group, Inc. for the fir...
December 9, 2022, 2:30 pm
replimune announces pricing of public offering
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — replimune Group, Inc. (Nasdaq: REPL), a clinical stage biote...
December 9, 2022, 2:04 am